An Appraisal of the Current Guidelines for the Use of Antifungals in the Treatment of Invasive Candidiasis, Aspergillosis, and Mucormycosis

Evaluation of fluconazole, itraconazole, and voriconazole activity on Candida albicans: A case control study

“…The Infectious Disease Society of America (IDSA) recommends the antifungal caspofungin, amphotericin B, or intravenous voriconazole as empiric therapy. Alternatively, fluconazole or itraconazole may be used [ 1 , 11 ]. Fluconazole has a broad spectrum, high efficiency, and good bioavailability and safety profile, so it is recommended as the first choice for treating Candida spp infections.…”

“…Several molecular resistance mechanisms have been identified, including changes in the gene encoding the ERG11 target enzyme or overexpression of efflux pump genes (CDR1, CDR2, and MDR1). Cross-resistance was observed with the antifungal (fluconazole, clotrimazole, itraconazole, and ketoconazole) [ 4 , 11 , 14 ].…”